Monoclonal Antibody Against Sortilin Induces Apoptosis in Human Breast Cancer Cells

Miganoosh Simonian; Mozhan Haji Ghaffari; Ali Salimi; Ebrahim Mirzadegan; Niloufar Sadeghi; Nasim Ebrahimnezhad; Ghazaleh Fazli; Ramina Fatemi; Ali-Ahmad Bayat; Saeideh Milani; Babak Negahdari; Hodjattallah Rabbani

doi:10.18502/ajmb.v14i1.8168

Monoclonal Antibody Against Sortilin Induces Apoptosis in Human Breast Cancer Cells

Avicenna J Med Biotechnol. 2022 Jan-Mar;14(1):37-45. doi: 10.18502/ajmb.v14i1.8168.

Affiliations

¹ Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
² Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
³ Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
⁴ Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.

Abstract

Background: Sortilin has an important role in various malignances and can be used as a promising target to eradicate cancer cells.

Methods: In this study, the expression of sortilin in 4T1 and MDA-MB231 cell lines was evaluated by flow cytometry and immunocytochemistry. Apoptosis assay was also applied to evaluate apoptosis induction in 4T1 and MDA-MB231 cell lines.

Results: Based on cell surface flow cytometry results, anti-sortilin (2D8-E3) mAb could recognize sortilin molecules in 79.2% and 90.3% of 4T1 and MDA-MB231 cell-lines, respectively. The immunocytochemistry staining results confirmed sortilin surface expression. Apoptosis assay indicated that anti-sortilin mAb could induce apoptosis in 4T1 and MDA-MB231 cell lines.

Conclusion: Our study revealed the important role of surface sortilin in breast carcinoma cell survival and its possible application as a therapeutic agent in cancer targeted therapies.

Keywords: Breast cancer; Flow cytometry; Monoclonal antibody; Sortilin.